Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Repeat Stereotactic Radiation in Patients With Intraprostatic Tumor Recurrence (STEREO-RE-PRO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03438552
Recruitment Status : Recruiting
First Posted : February 19, 2018
Last Update Posted : January 10, 2019
Sponsor:
Information provided by (Responsible Party):
UNICANCER

Brief Summary:

Stereo-Re-Pro aims to provide further evidence of Stereotactic Body Radiotherapy (SBRT) as a supplementary non-invasive curative treatment for local recurrence following radiotherapy.

The objective of the first part of the trial (Phase I) is to select the recommended dose for salvage SBRT (either 5 x 6 Gy, 6 x 6 Gy, or 5 x 5 Gy) based on dose-limiting toxicity observed during the 18 weeks following the initiation of salvage-SBRT. Particular attention will be paid to the quality of life and tolerance of the treatment.

The objective of the second part of the trial (phase II) is to estimate the efficacy of the salvage-SBRT in terms of biochemical relapse-free survival rate.


Condition or disease Intervention/treatment Phase
Local Recurrence of Malignant Tumor of Prostate Radiation: Stereotactic Body Radiotherapy Phase 1 Phase 2

Detailed Description:

To date, no standard local treatment exists for patients with an intraprostatic recurrence after radiotherapy. A number of treatments options exist including: radical prostatectomy, brachytherapy, HIFU, cryotherapy, and stereotactic radiotherapy. These treatments are associated with a variety of genitourinary and gastrointestinal toxicities and complications. In recent years, stereotactic radiotherapy has been used to treat localized prostate cancer in the primary setting but also as a salvage treatment after failure of radiotherapy. The initial results of these studies are promising, with respect to survival and tolerance, but further studies are required to confirm these initial results.

The objective of STEREO-RE-PRO is to prospectively evaluate salvage SBRT for intraprostatic recurrent prostate cancer after primary external radiotherapy. This study will select patients for whom there is no standard local treatment.

After inclusion and non-inclusion criteria have been verified and the patient has consented, the site will register the screening and organize the baseline visit with the placement of fiducial markers within two months before the planned start of SBRT.

Once the fiducial placement has been performed and all eligibility criteria fully reviewed, the site will register the patient's participation so that the bio-statistician allocates the dose of SBRT. The dose will be allocated upon a model-based estimates provided by the statistical team and confirmed by the trial steering committee. Five or six fractions, at a level of 5 or 6 Gy per session (either 5 x 6 Gy, 6 x 6 Gy, or 5 x 5 Gy), will be delivered over a maximum of 12 days to provide a total dose of 25 to 36 Gy. During the treatment phase of the study, no study specific visits are scheduled and the patients will be followed as per standard of care.

A follow-up visit is planned at 6, 10, 18 weeks from the start of SBRT for safety evaluation. Subsequent follow-up visits are planned at 6, 9, 12, 18, 24, 30 and 36 months after the start of radiotherapy. Thereafter, yearly follow-up visits at 48, 60, and 72 months after starting SBRT will be planned after the initial 3-year follow-up period. M72 visit corresponds to the end of study visit.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 47 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Multi-center Study Evaluating the Efficacy of Repeat Stereotactic Radiation in Patients With Intraprostatic Tumor Recurrence After External Radiation Therapy
Actual Study Start Date : October 18, 2018
Estimated Primary Completion Date : November 2024
Estimated Study Completion Date : November 2027

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: SRBT at a total dose of 30Gy
Placement of fiducials marker seeds in the prostate followed by the administration of stereotactic body radiotherapy at 30 Gy (5 sessions at a level of 6 Gy each- 1 session per day) 30Gy is the first dose-level. During the treatment phase of the study, no study specific visits are scheduled and the patients will be followed as per standard of care.
Radiation: Stereotactic Body Radiotherapy
This radiotherapy may be administered with the CyberKnife® or a linear accelerator allowing stereotactic radiotherapy.

Experimental: SBRT at a total dose of 25Gy
Placement of fiducials marker seeds in the prostate followed by the administration of stereotactic body radiotherapy at 25 Gy (5 sessions at a level of 5 Gy each- 1 session per day) During the treatment phase of the study, no study specific visits are scheduled and the patients will be followed as per standard of care.
Radiation: Stereotactic Body Radiotherapy
This radiotherapy may be administered with the CyberKnife® or a linear accelerator allowing stereotactic radiotherapy.

Experimental: SBRT at a total dose of 36Gy
Placement of fiducials marker seeds in the prostate followed by the administration of stereotactic body radiotherapy at 36 Gy (6 sessions at a level of 6 Gy each- 1 session per day) During the treatment phase of the study, no study specific visits are scheduled and the patients will be followed as per standard of care.
Radiation: Stereotactic Body Radiotherapy
This radiotherapy may be administered with the CyberKnife® or a linear accelerator allowing stereotactic radiotherapy.




Primary Outcome Measures :
  1. Selection of the recommended dose for salvage-SBRT (either 5 x 6 Gy, 6 x 6 Gy, or 5 x 5 Gy) based on dose-limiting toxicity observed during the 18 weeks following the initiation of salvage-SBRT. [ Time Frame: 18 weeks ]
    The dose-escalation part of the study will terminate once 10 patients have been treated and evaluated at a dose currently identified as the recommended dose.

  2. Estimate the efficacy of the salvage-SBRT in terms of biochemical relapse-free survival rate [ Time Frame: 6 years ]

Secondary Outcome Measures :
  1. Evaluation of acute and late genitourinary toxicities of the salvage-SBRT [ Time Frame: 3 years ]
    Acute and late genitourinary toxicities over the first 3 years according to the NCI-CTCAE V4.03 classification (June 14th, 2010)

  2. Estimate the efficacy of the salvage-SBRT in terms of clinical progression-free survival and overall survival [ Time Frame: 6 years ]
    Clinical progression-free survival is defined as the time interval between the date of registration and the date of clinical progression (local progression assessed by the physical examination, or appearance of metastatic lesions) or death irrespective of the cause.

  3. Evaluation of Quality of life after salvage-SBRT [ Time Frame: 6 years ]
    Quality of life will be evaluated based on the EORTC QLQ-C30. The Time Until Definitive Deterioration (TUDD) will be computed from registration until the first observation of a definitive deterioration of the quality of life, defined as a score decreased by 10 points (in the case of global health scale and functional scales) or increased by 10 points (in the case of symptom scales) compared to the score at baseline, without later improvement superior to 10 points compared to baseline score.

  4. Evaluation of Quality of life after salvage-SBRT [ Time Frame: 6 years ]
    Quality of life will be evaluated based on the EORTC QLQ-PR25. The Time Until Definitive Deterioration (TUDD) will be computed from registration until the first observation of a definitive deterioration of the quality of life, defined as a score decreased by 10 points (in the case of global health scale and functional scales) or increased by 10 points (in the case of symptom scales) compared to the score at baseline, without later improvement superior to 10 points compared to baseline score.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Biochemical recurrence occurring at least 2 years after external radiotherapy for prostatic adenocarcinoma by the Phoenix definition (PSA nadir + 2 ng/mL)
  • T1-T2c and PSA ≤20 ng/mL and Gleason score ≤7 at initial diagnosis of prostate cancer before the initial/first treatment.
  • Recurrence of prostatic adenocarcinoma proven by histology following radiotherapy by transrectal or transperineal sextant biopsies of the two lobes of the prostate, with a minimum of 12 biopsies, irrespective of Gleason score. Biopsies of the seminal vesicles are optional.
  • Clinical stage T1-T2 on relapse; unilateral extracapsular extension (T3a) on MRI permitted except posteriorly relative to the rectum
  • Estimated clinical target volume (CTV) / prostate volume < 0.5 based on imaging and biopsies
  • Pelvic and prostatic assessment by multiparametric MRI- Absence of pelvic or metastatic recurrence proven by choline PET scan
  • Performance status WHO 0-1
  • PSA level ≤10 ng/mL at baseline (before salvage-SBRT)
  • PSA doubling time >10 months
  • International Prostate Cancer Score (IPSS) ≤12
  • Uroflowmetry with a maximum flow rate >10 mL/s, a postvoid residual urine volume <150 mL, and a urine volume >150 mL.
  • No other anti-cancer treatment since the external radiotherapy administered as first-line treatment
  • No other anti-cancer treatment planned for the current recurrence
  • No contraindication to fiducial marker implants; haemostatic disorders must be corrected before implantation
  • Age >18 years
  • Life-expectancy greater than or equal to 5 years (Lee scale)
  • Patient registered with a health insurance system
  • Patient who has signed the informed consent form
  • Patients willing and able to comply with the scheduled visits, treatment plan, laboratory tests, and other study procedures indicated in the protocol.

Exclusion Criteria:

  • Lymph node or metastatic spread
  • Late post-radiotherapy urinary or gastrointestinal toxicity of grade ≥2 (following primary radiotherapy)
  • Other cancers in the last 5 years except for non-melanoma-type skin cancer
  • History of inflammatory bowel disease
  • Anticoagulant treatment
  • Contraindications to undergoing MRI
  • Prostate volume >80 cc
  • Transurethral resection of the prostate (TURP) in the 6 months before registrations
  • Presence of rectal telangiectasia grade 3 classified by the Vienne Rectoscopy Score (obligatory rectoscopy)
  • Previous rectal surgery
  • Patients unable to undergo medical follow-up in the study for geographical, social or psychological
  • Person deprived of their liberty or under protective custody or guardianship
  • Patients enrolled in another therapeutic study

All patients during the SBRT planning with a ratio of clinical target volume (CTV) / prostate volume > 0.5 will be withdrawn from the study. These patients will be considered as not evaluable and will not be treated within the context of the study.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03438552


Contacts
Layout table for location contacts
Contact: Soazig NENAN +33 (0)185 343 113 s-nenan@unicancer.fr
Contact: Meryem BRIHOUM +33 (0)1 80 50 12 95 m-brihoum@unicancer.fr

Locations
Layout table for location information
France
Centre François Baclesse Not yet recruiting
Caen, France
Contact: Emmanuel MEYER    +332 31 45 50 02    e.meyer@baclesse.unicancer.fr   
Principal Investigator: Emmanuel MEYER         
Centre Jean Perrin Recruiting
Clermont-Ferrand, France
Contact: Geneviève LOOS    04 73 27 81 42    genevieve.loos@clermont.unicancer.fr   
Principal Investigator: Geneviève LOOS         
Centre George François Leclerc Not yet recruiting
Dijon, France
Contact: Magali QUIVRIN    +33 (0)380 737 518    mquivrin@cgfl.fr   
Principal Investigator: Magali QUIVRIN         
Centre Oscar Lambret Recruiting
Lille, France
Contact: David PASQUIER    + 33(0) 320 295 911    d-pasquier@o-lambret.fr   
Principal Investigator: David PASQUIER         
Centre Léon Bérard Not yet recruiting
Lyon, France
Contact: Pascal POMMIER    +33(0)478 785 166    pascal.pommier@lyon.unicancer.fr   
Principal Investigator: Pascal Pommier         
Institut régional du Cancer de Montpellier Not yet recruiting
Montpellier, France
Contact: David AZRIA    04 67 61 31 32    david.azria@icm.unicancer.fr   
Principal Investigator: David AZRIA         
Groupe Hospitalier Pitié-Salpétrière Not yet recruiting
Paris, France
Contact: Philippe MAINGON    01 84 82 72 76    philippe.maingon@aphp.fr   
Principal Investigator: Philippe MAINGON         
CHU de Poitiers Not yet recruiting
Poitiers, France, 86000
Contact: Stéphane GUERIF    +33(0)5 49 44 44 85    stephane.guerif@chu-poitiers.fr   
Principal Investigator: Stéphane GUERIF         
ICO -Site René Gauducheau Recruiting
Saint-Herblain, France
Contact: Stephane SUPIOT    +33 (0)240 679 900    stephane.supiot@ico.unicancer.fr   
Principal Investigator: Stephane SUPIOT         
Institut de Cancérologie Lucien Neuwirth Not yet recruiting
Saint-Priest-en-Jarez, France
Contact: Nicolas MAGNE    04 77 91 71 04    nicolas.magne@icloire.fr   
Principal Investigator: Nicolas MAGNE         
CHRU Henry S.Kaplan Recruiting
Tours, France, 37044
Contact: Guillaume JANORAY    +33(0)2 47 47 82 65    g.janoray@chu-tours.fr   
Principal Investigator: Guillaume JANORAY         
Institut de Cancérologie de Lorraine Recruiting
Vandoeuvre-les-nancy, France, 54519
Contact: Didier PEIFFERT    +33(0)3 83 59 84 31    d.peiffert@nancy.unicancer.fr   
Principal Investigator: Didier PEIFFERT         
Sponsors and Collaborators
UNICANCER
Investigators
Layout table for investigator information
Principal Investigator: David Pasquier Centre Oscar Lambret, LILLE

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: UNICANCER
ClinicalTrials.gov Identifier: NCT03438552     History of Changes
Other Study ID Numbers: GETUG-AFU 31 - UC-0160/1618
2017-A00008-45 ( Registry Identifier: ID RCB number )
First Posted: February 19, 2018    Key Record Dates
Last Update Posted: January 10, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Recurrence
Neoplasms
Disease Attributes
Pathologic Processes
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases